144 related articles for article (PubMed ID: 28434969)
1. Translational science approach for assessment of cardiovascular effects and proarrhythmogenic potential of the beta-3 adrenergic agonist mirabegron.
Korstanje C; Suzuki M; Yuno K; Sato S; Ukai M; Schneidkraut MJ; Yan GX
J Pharmacol Toxicol Methods; 2017 Sep; 87():74-81. PubMed ID: 28434969
[TBL] [Abstract][Full Text] [Related]
2. The risk and severity of developing symptomatic palpitations when prescribed mirabegron for overactive bladder.
Balachandran AA; Duckett JR
Eur J Obstet Gynecol Reprod Biol; 2015 Apr; 187():60-3. PubMed ID: 25756594
[TBL] [Abstract][Full Text] [Related]
3. Mirabegron: a safety review.
Tyagi P; Tyagi V; Chancellor M
Expert Opin Drug Saf; 2011 Mar; 10(2):287-94. PubMed ID: 21142693
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome.
Rosa GM; Ferrero S; Nitti VW; Wagg A; Saleem T; Chapple CR
Eur Urol; 2016 Feb; 69(2):311-23. PubMed ID: 26422675
[TBL] [Abstract][Full Text] [Related]
5. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
Gillespie JI; Palea S; Guilloteau V; Guerard M; Lluel P; Korstanje C
BJU Int; 2012 Jul; 110(2 Pt 2):E132-42. PubMed ID: 22734512
[TBL] [Abstract][Full Text] [Related]
6. Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.
Tyagi P; Tyagi V
IDrugs; 2010 Oct; 13(10):713-22. PubMed ID: 20878594
[TBL] [Abstract][Full Text] [Related]
7. An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron-Induced Cardiovascular Effects.
van Gelderen M; Stölzel M; Meijer J; Kerbusch V; Collins C; Korstanje C
J Clin Pharmacol; 2017 Dec; 57(12):1534-1544. PubMed ID: 28618007
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia.
Sawada N; Nomiya M; Hood B; Koslov D; Zarifpour M; Andersson KE
Eur Urol; 2013 Oct; 64(4):664-71. PubMed ID: 23838637
[TBL] [Abstract][Full Text] [Related]
10. Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men.
van Gelderen M; Tretter R; Meijer J; Dorrepaal C; Gangaram-Panday S; Brooks A; Krauwinkel W; Dickinson J
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):693-701. PubMed ID: 24755125
[TBL] [Abstract][Full Text] [Related]
11. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.
Malik M; van Gelderen EM; Lee JH; Kowalski DL; Yen M; Goldwater R; Mujais SK; Schaddelee MP; de Koning P; Kaibara A; Moy SS; Keirns JJ
Clin Pharmacol Ther; 2012 Dec; 92(6):696-706. PubMed ID: 23149929
[TBL] [Abstract][Full Text] [Related]
12. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
[TBL] [Abstract][Full Text] [Related]
13. mirabegron (BETMIGA⁰). Poorly effective in urge urinary incontinence.
Prescrire Int; 2016 Jan; 25(167):8. PubMed ID: 26942249
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females.
Nomura Y; Iitsuka H; Toyoshima J; Kuroishi K; Hatta T; Kaibara A; Katashima M; Moy S; Sawamoto T
Drug Metab Pharmacokinet; 2016 Dec; 31(6):411-416. PubMed ID: 27829538
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.
Michel MC; Gravas S
Expert Opin Drug Saf; 2016 May; 15(5):647-57. PubMed ID: 26954275
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
17. MS-551 and KCB-328, two class III drugs aggravated adrenaline-induced arrhythmias.
Xue Y; Yamada C; Aye NN; Hashimoto K
Br J Pharmacol; 1998 Aug; 124(8):1712-8. PubMed ID: 9756388
[TBL] [Abstract][Full Text] [Related]
18. New in vitro model for proarrhythmia safety screening: IKs inhibition potentiates the QTc prolonging effect of IKr inhibitors in isolated guinea pig hearts.
Kui P; Orosz S; Takács H; Sarusi A; Csík N; Rárosi F; Csekő C; Varró A; Papp JG; Forster T; Farkas AS; Farkas A
J Pharmacol Toxicol Methods; 2016; 80():26-34. PubMed ID: 27063345
[TBL] [Abstract][Full Text] [Related]
19. The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication?
Calmasini FB; Candido TZ; Alexandre EC; D'Ancona CA; Silva D; de Oliveira MA; De Nucci G; Antunes E; Mónica FZ
Prostate; 2015 Mar; 75(4):440-7. PubMed ID: 25417911
[TBL] [Abstract][Full Text] [Related]
20. The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity.
Svalø J; Nordling J; Bouchelouche K; Andersson KE; Korstanje C; Bouchelouche P
Eur J Pharmacol; 2013 Jan; 699(1-3):101-5. PubMed ID: 23246623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
